Tudor Investment Corp’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
VC
RSCM
RCM
SB
Tudor Investment Corp's ACRS Position: Q4 2024 in Review
Tudor Investment Corp sold out of Aclaris Therapeutics (ACRS) in Q4 2024, closing a stake of 33,183 shares — an estimated $38.2K sold.
Tudor Investment Corp first reported a position in ACRS in Q4 2017 and held it in 16 quarters. The position peaked at $344K in Q2 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q4 2024.
- Tudor Investment Corp reported no remaining Aclaris Therapeutics position as of Q4 2024 after selling out during the quarter.
- Tudor Investment Corp sold 33,183 Aclaris Therapeutics shares in Q4 2024, an estimated $38.2K.
- Tudor Investment Corp first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 16 quarters.
- Tudor Investment Corp's Aclaris Therapeutics position peaked at $344K in Q2 2023.
- 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2024.
Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.